MULTIPLE MYELOMA

Beginning with bortezomib (Velcade) in 2004, there have been 10 agents approved over the last 12 years for the treatment of patients with multiple myeloma.

Pembrolizumab (Keytruda), pomalidomide (Pomalyst), and dexamethasone had an objective response rate of 65% and a very good partial response or better rate of 29% for patients with relapsed/refractory multiple myeloma, according to phase II findings presented at the 2016 ASH Annual Meeting.

Data from a prospective assessment of minimal residual disease from the phase III CASTOR and POLLUX studies demonstrated at least a 3-fold increase in conversion to negative MRD status with the addition of daratumumab (Darzalex) to standard-of-care regimens in the treatment of patients with relapsed/refractory multiple myeloma.

Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses the efficacy seen with venetoclax in multiple myeloma during the ASH Annual Meeting 2016.

Consolidation therapy with bortezomib/lenalidomide/dexamethasone (VRD) followed by maintenance with lenalidomide until progression or toxicity showed promising results over maintenance alone for patients with transplant-eligible multiple myeloma (NDMM) up to 65 years old, according to a final analysis of the EMN02 trial.

The European Commission has granted a conditional approval to ixazomib (Ninlaro) in combination with lenalidomide and dexamethasone for adult patients with multiple myeloma.

IMiD Sequencing in Relapsed Myeloma with Keith Stewart, MB, ChB

IMiD Sequencing in Relapsed Myeloma with Keith Stewart, MB, ChB

Clinical trial findings from the past year will likely have a game-changing effect on the multiple myeloma landscape, according to Rafael Fonseca, MD.

Daratumumab (Darzalex) has received FDA approval in combination with lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.

IMiD Sequencing in Relapsed Multiple Myeloma with Paul G. Richardson, MD

IMiD Sequencing in Relapsed Multiple Myeloma with Paul G. Richardson, MD

The availability of several new treatments has dramatically transformed the treatment paradigm for multiple myeloma in the past few years.

The key to inducing durable responses with immunotherapy in multiple myeloma may depend on the effective use of combination strategies, particularly for the use of monoclonal antibodies.

Denosumab (Xgeva) was shown to be noninferior to zoledronic acid (Zometa) at delaying skeletal-related events (SREs) for patients with multiple myeloma.

George Somlo, MD, medical oncologist, City of Hope, discusses recent advancements in multiple myeloma treatment.

The current treatment landscape for relapsed and refractory multiple myeloma is so promising, oncologists should not hesitate to consider integrating novel therapies into multiple myeloma management, Kenneth C. Anderson, MD, said.

<em>Targeted Oncology</em> speaks with Shaji Kumar, MD, to understand the roles that the new criteria for response and minimal residual disease (MRD) assessment in multiple myeloma&nbsp;and what role MRD testing will play going forward in multiple myeloma.<br /> &nbsp;